Skip to search formSkip to main contentSkip to account menu

Tradjenta

Known as: Trajenta 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

Linagliptin
Linagliptin 5 MG Oral Tablet [Tradjenta]Linagliptin Oral Tablet [Tradjenta]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Arthralgies et arthrites d’origine médicamenteuses, rares ou émergentes
Review
2017
Review
2017
Comparative Study of Different Brands of Linagliptin Tablet with Innovator drug
Linagliptin is a dipeptidyl peptidase 4 (DPP-4) inhibitors developed by Boehringer Ingelheim,which can be used to treat diabetes… 
2015
2015
Analysis of the clinical efficacy and safety of trajenta combined with acarbose in the treatment of senile diabetes
Objective:To investigate the clinical efficacy and the adverse reaction of trajenta combined with acarbose in the treatment of… 
Review
2013
Review
2013
[Oral Linagliptin (Trajenta)].
2012
2012
[Linagliptin (Trajenta): a selective DPP-4 inhibitor with limited renal elimination].
Linagliptin (Trajenta) is a selective inhibitor of dipeptidyl peptidase-4, an enzyme that degrades two incretin hormones, GLP-1… 
2012
2012
Le medicament du mois: Linagliptine (Trajenta): un inhibiteur selectif de la DPP-4 a elimination renale negligeable.
La linagliptine (Trajenta ® ) est un inhibiteur selectif de la dipeptidyl peptidase-4, l'enzyme qui degrade les deux hormones… 
2011
2011
Trajenta, INN-linagliptin
  • 2011
  • Corpus ID: 44829142
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)